Akari Therapeutics Plc Quick ratio

What is the Quick ratio of Akari Therapeutics Plc?

The Quick ratio of Akari Therapeutics Plc is 2.68

What is the definition of Quick ratio?



Quick ratio is liquidity ratio that measures a company’s ability to use its quick assets to meet its short-term obligations immediately.

mrq (most recent quarter)

The quick ratio is the ratio between quick or liquid assets and current liabilities. Quick assets include those current assets that presumably can be quickly converted to cash at close to their book values. A normal liquid ratio is considered to be 1. A company with a quick ratio of less than 1 cannot at the time fully pay its current liabilities or short-term obligations. This ratio is considered to be a much reliable tool for assessment of liquidity position of companies.

Quick ratio of companies in the Health Care sector on NASDAQ compared to Akari Therapeutics Plc

What does Akari Therapeutics Plc do?

akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.

Companies with quick ratio similar to Akari Therapeutics Plc